Diagens Biotechnology

Diagens Biotechnology (Ticker: 2526 HK) develops medical imaging products and services, including software that supports chromosome analysis for prenatal diagnosis and assisted reproduction. Its AI AutoVision software assists with chromosome karyotyping analysis, the examination of chromosomes used in prenatal diagnosis and assisted reproduction. The company profile reports that China’s National Medical Products Administration recognized its core technology as a Class III Innovative Medical Device, a designation described as allowing an expedited regulatory path. Planned uses of proceeds include research and development, production capacity, brand promotion, business development, working capital and strategic acquisitions.

The scheduled listing date on Hong Kong Stock Exchange was March 30, 2026. The offering comprises 8,000,000 shares at a confirmed price of HKD 99.00 per share. At the confirmed offer price, the base offering represents HKD 792.00 million, approximately $100.92 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $1.12 billion.

Huatai Financial Holdings is the sponsor. ABCI Capital, BOCI Asia and CCB International are the management group.